124 related articles for article (PubMed ID: 1093666)
1. Comparison of adriamycin (NSC-123127) and the combination of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in advanced prostatic cancer: a preliminary report.
Eagan RT; Utz DC; Myers RP; Furlow WL
Cancer Chemother Rep; 1975; 59(1):203-7. PubMed ID: 1093666
[TBL] [Abstract][Full Text] [Related]
2. Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer.
Eagan RT; Hahn RG; Myers RP
Cancer Treat Rep; 1976 Jan; 60(1):115-7. PubMed ID: 1000515
[No Abstract] [Full Text] [Related]
3. Combination chemotherapy with methotrexate (NSC-740), adriamycin (NSC-123127), cyclophosphamide (NSC-26271), and 5-fluorouracil (NSC19893) for adult solid tumors.
Stephens RL; Hoogstraten B
Cancer Chemother Rep; 1974; 58(6):943-5. PubMed ID: 4614901
[No Abstract] [Full Text] [Related]
4. Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin.
Merrin C; Etra W; Wajsman Z; Baumgartner G; Murphy G
J Urol; 1976 Jan; 115(1):86-8. PubMed ID: 1107604
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma.
Collier D; Soloway MS
Urology; 1976 Nov; 8(5):459-64. PubMed ID: 982733
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial.
Chlebowski RT; Hestorff R; Sardoff L; Weiner J; Bateman JR
Cancer; 1978 Dec; 42(6):2546-52. PubMed ID: 365313
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial.
Lloyd RE; Jones SE; Salmon SE; Durie BG; McMahon LJ
Cancer Treat Rep; 1976 Jan; 60(1):77-83. PubMed ID: 1000520
[TBL] [Abstract][Full Text] [Related]
8. Comparison of adriamycin (NSC-123127) and 5-fluorouracil (NSC-19893) in advanced prostatic cancer.
DeWys WD
Cancer Chemother Rep; 1975; 59(1):215-7. PubMed ID: 1093668
[No Abstract] [Full Text] [Related]
9. Evaluation of chemotherapeutic responsiveness in Nb rat prostate cancer model. 5-fluorouracil, methotrexate, cyclophosphamide, and adriamycin.
Drago JR; Goldman L; Gershwin ME
Invest Urol; 1980 Jul; 18(1):80-1. PubMed ID: 7410017
[TBL] [Abstract][Full Text] [Related]
10. Adriamycin (NSC-123127) plus 5-fluorouracil (NSC-19893): a phase I study.
Tranum BL; Stephens RL; Lehane DE; Hoogstraten B; Lane M; Haut A
Cancer Chemother Rep; 1975; 59(6):1163-5. PubMed ID: 769959
[No Abstract] [Full Text] [Related]
11. Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation.
Muggia FM; Perloff M; Chia GA; Reed LJ; Escher GC
Cancer Chemother Rep; 1974; 58(6):919-26. PubMed ID: 4614899
[No Abstract] [Full Text] [Related]
12. Adriamycin-cyclophosphamide and adriamycin-cis-dichloro-diammineplatinum(II) combination chemotherapy in patients with advanced cancer.
Higby DJ; Wilbur D; Wallace HJ; Henderson ES; Weiss R
Cancer Treat Rep; 1977 Aug; 61(5):869-73. PubMed ID: 329980
[TBL] [Abstract][Full Text] [Related]
13. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.
Bull JM; Tormey DC; Li SH; Carbone PP; Falkson G; Blom J; Perlin E; Simon R
Cancer; 1978 May; 41(5):1649-57. PubMed ID: 348293
[TBL] [Abstract][Full Text] [Related]
14. Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer.
Ahmann DL; Bisel HF; Eagan RT; Edmonson JH; Hahn RG
Cancer Chemother Rep; 1974; 58(6):877-82. PubMed ID: 4614896
[No Abstract] [Full Text] [Related]
15. Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate.
Bruckner HW; Deppe G
Obstet Gynecol; 1977 Jul; 50(1 Suppl):10s-12s. PubMed ID: 876531
[TBL] [Abstract][Full Text] [Related]
16. Muehrcke's lines on nails after cyclophosphamide/adriamycin/fluorouracil.
Gül U; Kiliç A
Ann Pharmacother; 2004 Jun; 38(6):1089-90. PubMed ID: 15122002
[No Abstract] [Full Text] [Related]
17. Treatment of metastatic breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy.
Abeloff MD; Ettinger DS
Cancer Treat Rep; 1977 Dec; 61(9):1685-9. PubMed ID: 340033
[TBL] [Abstract][Full Text] [Related]
18. Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone.
Frederiksen PL; Joergensen ST; Roesdahl K; Thomsen J; Mouridsen HT
Cancer Treat Rep; 1978 Mar; 62(3):449-50. PubMed ID: 348314
[No Abstract] [Full Text] [Related]
19. Combination chemotherapy for metastatic breast cancer: comparison of multiple drug therapy with 5-fluorouracil, cytoxan and prednisone with adriamycin or adrenalectomy.
Nemoto T; Rosner D; Diaz R; Dao T; Sponzo R; Cunningham T; Horton J; Simon R
Cancer; 1978 Jun; 41(6):2073-7. PubMed ID: 657080
[No Abstract] [Full Text] [Related]
20. A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma.
Smalley RV; Bartolucci AA; Hemstreet G; Hester M
J Urol; 1981 Feb; 125(2):191-5. PubMed ID: 7206052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
